Immune responses associated with perioperative exposure and reexposure to topical bovine thrombin do not impair hemostasis

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 6, 2011, Pages 620-632

  Paterson, Craig A ^a   Pixton, Glenn C ^a   Proskin, Howard M ^b   Massaro, Joseph M ^c   Morasch, Mark ^d   Cronstein, Bruce ^e   Fareed, Jawed ^f   Ofosu, Frederick A ^g  

^a PFIZER INC   (United States)

^b Howard M Proskin & Associates Inc   (United States)

^c BOSTON UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

exposure; hemostasis; immune responses; topical bovine thrombin

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN ANTIBODY; RECOMBINANT THROMBIN; THROMBIN; THROMBOPLASTIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBODY TITER; BLOOD CLOTTING DISORDER; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SAFETY; DYSPNEA; FEMALE; FOLLOW UP; HEMOSTASIS; HIP ARTHROPLASTY; HUMAN; IMMUNE RESPONSE; INTERVERTEBRAL DISKECTOMY; JOINT PROSTHESIS; LAMINECTOMY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 4 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SPINE SURGERY; THROMBIN TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CATTLE; COHORT STUDIES; HEMOSTATICS; HUMANS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; THROMBIN; YOUNG ADULT;

EID: 81855162997     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611405187     Document Type: Review

References (20)

1. Jackson MR, MacPhee MJ, Drohan WN, Alving BM. Fibrin sealant: current and potential clinical applications. Blood Coagul Fibrinolysis. 1996 ; 7 (8). 737-746 (Pubitemid 27051187)
2. Ofosu FA, Crean S, Reynolds MW. A safety review of topical bovine thrombin-induced generation of antibodies to bovine proteins. Clin Ther. 2009 ; 31 (4). 679-691
3. Lundblad RL, Bradshaw RA, Gabriel D, Ortel TL, Lawson J, Mann KG. A review of the therapeutic uses of thrombin. Thromb Haemost. 2004 ; 91 (5). 851-860 (Pubitemid 38647487)
4. Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res. 2001 ; 58 (6). 710-719 (Pubitemid 33096572)
5. Cheng CM, Meyer-Massetti C, Kayser SR. A review of three stand-alone topical thrombins for surgical hemostasis. Clin Ther. 2009 ; 31 (1). 32-41
6. Terrab A, Pawlak D, Spaay P, Hoppensteadt D, Fareed J. Further removal of factor v related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost. 2008 ; 14 (2). 135-140 (Pubitemid 351364022)
7. Flaherty MJ, Wener MH. Antibodies to thrombin in postsurgical patients. Blood. 1989 ; 73 (5). 1386
8. Diez-Martin J, Sikkink RA, Gilchrist GS, Bowie EJ, Fass DN. Development of anti-bovine thrombin antibodies following neurosurgical procedures. Br J Haematol. 1990 ; 74 (3). 369-370 (Pubitemid 20106070)
9. La Spada AR, Skalhegg BS, Henderson R, Schmer G, Pierce R, Chandler W. Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med. 1995 ; 333 (8). 494-497
10. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990 ; 76 (10). 2011-2016
11. Rapaport SI, Zivelin A, Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 1992 ; 97 (1). 84-91
12. Chouhan VD, De La Cadena RA, Nagaswami C, Weisel JW, Kajani M, Rao AK. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost. 1997 ; 77 (2). 343-349 (Pubitemid 27084928)
13. Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin. 2008 ; 24 (3). 785-794 (Pubitemid 351428990)
14. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007 ; 205 (2). 256-265 (Pubitemid 47095423)
15. Bristol, TN: King Pharmaceuticals, Inc ; 2007 :
16. Winterbottom N, Kuo JK, Nguyen K, et al. Antigenic responses to bovine thrombin exposure during surgery: a prospective study of 309 patients. J Appl Res. 2010 ; 2 (3). 20-29
17. D'Agostino RB,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998 ; 17 (19). 2265-2281
18. Kamal AH, Tefferi A, Pruthi RK. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc. 2007 ; 82 (7). 864-873 (Pubitemid 47015468)
19. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001 ; 233 (1). 88-96 (Pubitemid 32043608)
20. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Ann Intern Med. 2006 ; 145 (1). 62-69 (Pubitemid 46780603)